Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma

Inclusion Criteria

• •1. Willingness to participate in the clinical study.
• •2. Age ≥ 18 years at the time of signing the Informed Consent Form (ICF).
• •3. Newly diagnosed ENKTL confirmed by histopathology at the study center.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• •5. At least one evaluable or measurable lesion
• •6. Ann Arbor stage I-II disease.
• •7. PINK-E score ≥ 1.
• •8. Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or abnormalities in cardiac, pulmonary, hepatic, renal, or thyroid function, and no immunodeficiency.